Show Summary Details
Page of

Meticillin-resistant Staphylococcus aureus bacteraemia 

Meticillin-resistant Staphylococcus aureus bacteraemia
Meticillin-resistant Staphylococcus aureus bacteraemia

James Price

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 30 June 2022

Although rates of MRSA bacteraemia have fallen markedly in the UK, S. aureus bacteraemia remains a common clinical entity associated with substantial morbidity and mortality. This case illustrates the key elements of optimal management. Early diagnosis and prompt initiation of treatment are crucial. Unless the infection is known to be caused by MRSA, treatment should include a beta-lactam drug where possible. It is not established whether using combination antibiotic therapy improves outcome. Foci of infection must be identified promptly by thorough and repeated clinical examination and radiological investigation and removed as soon as possible. Current best evidence indicates that patients with S. aureus bacteraemia should receive intravenous treatment for a minimum of 2 weeks, with this duration increasing to 4–6 weeks in patients with endocarditis or unremovable foci of infection.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.